ALK fusions in the pan-cancer setting: another tumor-agnostic target?
Aditya Shreenivas(Medical College of Wisconsin), Razelle Kurzrock(Medical College of Wisconsin), Mohamed A. Gouda(The University of Texas MD Anderson Cancer Center), Filip Jankú(The University of Texas MD Anderson Cancer Center), Shumei Kato(University of California San Diego), Ben George(Medical College of Wisconsin), Hui‐Zi Chen(The Ohio State University)
Cited by 89
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
|Molecular Cancer Therapeutics|2015|2.3k
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
|Blood|2016|1.6k
Landscape of Microsatellite Instability Across 39 Cancer Types
|JCO Precision Oncology|2017|1.5k
Epstein-Barr Virus and Cancer
|Clinical Cancer Research|2004|795